Onxeo Reports First-Half 2016 Business Update And Consolidated Financials

PARIS & COPENHAGEN--(BUSINESS WIRE)--Regulatory News:

Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today reported its consolidated half-year financials as of June 30, 2016 and provided an update on the key operational and clinical milestones reached during the first six months of the year.

MORE ON THIS TOPIC